Академический Документы
Профессиональный Документы
Культура Документы
com/research/big-pharma-investing-private-markets/
The most active pharma investors since 2014 are Novartis, Johnson & Johnson,
GlaxoSmithKline, Pfizer, and Celgene.
In addition to these challenges, pharma corporates face the outsized costs and time
commitment required of basic R&D. Consequently, big players in the industry have
taken to outsourcing much of the basic science that goes into drug discovery. These
companies often acquire promising startups in order to further develop their
technology and bring it forward to commercialization. A few are also investing heavily
in digital health, making bets across genomics, medication management, and
connected devices.
We used CB Insights’ Business Social Graph to analyze where the top pharma
companies are making their private market deals.
Allergan
Bayer
Biogen
1 of 5 12/14/2017, 7:41 AM
Where They're Investing Across Genomics, Biotech, and Digital Health https://www.cbinsights.com/research/big-pharma-investing-private-markets/
Celgene
Gilead
GlaxoSmithKline, SR One
2 of 5 12/14/2017, 7:41 AM
Where They're Investing Across Genomics, Biotech, and Digital Health https://www.cbinsights.com/research/big-pharma-investing-private-markets/
Key Takeaways:
So far this year, there have been 47 equity deals with participation from one of the top
20 public pharma corporates. Deals from this group fell 13% last year from 121 in
2015 to 105 in 2016 but are currently on track to pick up this year.
The top 5 most active pharma investors since 2014 are Novartis, Johnson & Johnson,
GlaxoSmithKline, Pfizer, and Celgene. Novartis leads the pack with deals to 60
companies since 2014, most of which have gone through their venture arm Novartis
Venture Funds.
The largest equity deal since 2014 with participation from one of the top 20 pharma
corporates is the $914M Series B of GRAIL with participation from Johnson &
Johnson, Merck, Bristol-Myers Squibb, and Celgene. In a distant second, Verily and
Sanofi took a $500M minority stake in Onduo in September 2016.
Track all the pharma startups in this brief and many more on our
platform
Startups working in oncology, infectious disease, genomic medicine, and many other
sectors are transforming the industry. Look for Pharma Startups in the Collections
tab.
Novartis invests across a range of technologies including, but not limited to,
telemedicine platforms, point-of-care diagnostics, oncology therapeutics, and skin
care products.
Since 2014, Novartis Venture Funds has participated in 3 or more rounds to Aerpio
3 of 5 12/14/2017, 7:41 AM
Where They're Investing Across Genomics, Biotech, and Digital Health https://www.cbinsights.com/research/big-pharma-investing-private-markets/
Johnson & Johnson has also developed a broad portfolio of medical devices,
microbiome therapeutics, and cancer diagnostics, to name a few.
Merck is by far the most active pharma corporate in digital health with over 20 deals
since 2014. This year, the Merck Global Health Innovation Fund has participated in
the $12M Series D of the healthcare cloud computing company ClearDATA and the
$30M equity round of Arcadia Healthcare Solutions, focused on data analytics for
health records.
A few startups received investment from multiple top pharma corporates. Examples
include:
CRISPR Therapeutics: Backed by Bayer, SR One (GlaxoSmithKline’s venture arm),
and Celgene. Went public in 2016 valued at $556M. CRISPR Therapeutics is a gene
editing company developing novel therapeutics for diseases such as beta-thalassemia,
sickle cell disease, and hemophilia.
Want more data on where pharmaceutical companies are investing? Check out
our private market database below.
4 of 5 12/14/2017, 7:41 AM
Where They're Investing Across Genomics, Biotech, and Digital Health https://www.cbinsights.com/research/big-pharma-investing-private-markets/
Related Research
Comments
5 of 5 12/14/2017, 7:41 AM